Acasti Pharma

Loading quotes...

Forecast

Buy	3
Hold	2
Sell	0

News Go to news feed

Acasti Pharma reports significant profit increase in the quarter

Acasti Pharma posted earnings per share of $0.05 in the past quarter, after reporting a loss of -$0.34 per share in the same period last year. For the full year, the loss per share was reduced to -$0.79, compared to -$1.35 the previous year. The figures indicate a marked improvement in the company's financial position. » More on finanzen.net

Financials

In the last quarter, Acasti Pharma had revenue of €0 and net profit of -€13.84m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-13.84m	385.04%
EBITDA	0	100.00%

Fundamentals

Metric	Value
Market capitalization	€30.53m
Number of shares	10.14m
52-week high/low	€3.22 - €1.77
Dividends	No
Beta	1.52
P/E ratio	-1.42
PEG ratio	0.01
P/B ratio	0.64
P/S ratio	0.00

Company profile

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.